Get the Stockscreener App
11.14
1.83%
0.20
After Hours:
11.16
0.02
+0.18%
Cullinan Therapeutics Inc stock is traded at $11.14, with a volume of 876.50K.
It is up +1.83% in the last 24 hours and down -10.45% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$10.94
Open:
$10.71
24h Volume:
876.50K
Relative Volume:
0.71
Market Cap:
$658.11M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-3.019
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
+7.63%
1M Performance:
-10.45%
6M Performance:
+51.56%
1Y Performance:
+0.09%
1-Day Range:
$10.60
$11.44
1-Week Range:
$9.41
$11.44
52-Week Range:
$5.68
$13.33
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
11.14 | 646.29M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Today's Analyst Ratings Update: CGEM Price Target Raised to $27 - GuruFocus
Cullinan Management Outlines Catalyst-Rich 2026 Pipeline Outlook - TipRanks
Cullinan Therapeutics (CGEM) Outlines Key Developments for 2026 - GuruFocus
Cullinan Therapeutics Outlines 2026 Milestones for CLN-978 and CLN-049 Programs, NDA Submission for Zipalertinib - Quiver Quantitative
Cullinan Therapeutics plans data readouts for key autoimmune programs By Investing.com - Investing.com UK
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones - GlobeNewswire
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 9.5%Here's Why - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (NQ:CGEM) - FinancialContent
Oncology Drugs Fast-Tracked by the FDA in December 2025 - Oncology News Central
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 3.9%What's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nadim Ahmed Sells 9,922 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Assenagon Asset Management S.A. Has $1.05 Million Stake in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (CGEM) price target increased by 19.75% to 32.84 - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat
Insider Sell: Jennifer Michaelson Sells Shares of Cullinan Thera - GuruFocus
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $13,463.45 in Stock - MarketBeat
Cullinan Therapeutics CSO Sells Shares - TradingView — Track All Markets
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $28,023.66 in Stock - Defense World
Cullinan Therapeutics (CGEM) Price Target Increased by 19.75% to 32.84 - Nasdaq
Will Cullinan Therapeutics Inc. stock deliver shareholder value2025 Price Targets & Weekly High Potential Stock Alerts - ulpravda.ru
Cullinan Therapeutics price target raised to $34 from $25 at Wedbush - MSN
Cullinan Therapeutics Earnings Notes - Trefis
Cullinan Therapeutics shows rising price performance with jump to 93 RS rating - MSN
Is Cullinan Therapeutics Inc. stock a contrarian buy2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - Улправда
Jacquelyn Sumer Sells 3,480 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Jeffrey Alan Jones Sells 4,632 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics Executives Sell Shares for Tax Obligations - TradingView — Track All Markets
Officer Michaelson Files To Sell 1,345 Of Cullinan Therapeutics Inc [CGEM] - TradingView — Track All Markets
How Cullinan Therapeutics Inc. stock reacts to inflationary pressures2025 Sector Review & Reliable Intraday Trade Plans - Улправда
Jobs Data: Will Cullinan Therapeutics Inc. stock deliver better than expected guidanceMarket Trend Summary & Technical Buy Zone Confirmations - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Cullinan Management (CGEM) - The Globe and Mail
Will Cullinan Therapeutics (NASDAQ:CGEM) Spend Its Cash Wisely? - Yahoo Finance
Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data - Investing.com Nigeria
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 2,148 Shares of Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 995 Shares - MarketBeat
Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates - Finviz
Cullinan Therapeutics presents promising CLN-049 data - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.5%What's Next? - MarketBeat
20 Stocks That Will Double in 2026 - Insider Monkey
Cullinan Therapeutics, Inc. (CGEM) Presents at The 67th American Society of Hematology (ASH) Annual MeetingSlideshow (NASDAQ:CGEM) 2025-12-11 - Seeking Alpha
Weekly Research Analysts’ Ratings Updates for Cullinan Therapeutics (CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 at Wedbush - Defense World
Wedbush Maintains Cullinan Therapeutics (CGEM) Outperform Recommendation - Nasdaq
Holdings of Cullinan Therapeutics Inc (CGEM) are aligned with the stars - setenews.com
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 - MarketBeat
Wedbush Raises Price Target on CGEM to $34, Maintains Outperform - GuruFocus
CGEM: CLN-049 demonstrates strong efficacy and safety in AML, advancing toward pivotal trials - TradingView — Track All Markets
Cullinan Therapeutics (NASDAQ:CGEM) Trading 9.3% HigherWhat's Next? - MarketBeat
Cullinan Oncology stock soars after promising AML treatment results By Investing.com - Investing.com Canada
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):